RIPK3 and hepatocellular carcinoma: Studies have revealed that in HCC, RIPK3 is downregulated in TAMs, leading to enhanced FA metabolism by reducing ROS production and inhibiting caspase-1-mediated peroxisome proliferator-activated receptor (PPAR) cleavage, thereby promoting PPAR activation and M2 polarization in the TME.